Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. ResApp Health Limited
  6. News
  7. Summary
    RAP   AU000000RAP5


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ResApp Health : First patients recruited in COVID-19 clinical study in India

09/19/2021 | 06:42pm EDT

View printer-friendly version

  • First patients recruited in Indian study to collect cough sounds from patients with suspected COVID-19
  • Study aims to recruit 220 participants, with recruitment expected to be complete by the end of October
  • ResApp aims to use the data to develop a smartphone-based algorithm to instantly screen for COVID-19 as well as monitor disease progression

Brisbane, Australia, 20 September 2021 - ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease today announced that it has recruited ten patients on the first day of its pilot study for the collection of cough sounds from patients with suspected COVID-19 in India (refer ASX announcement 9 August 2021). ResApp aims to use this data to develop a smartphone-based algorithm to instantly screen for COVID-19 and monitor disease progression.

Patient recruitment follows approval from an institutional review board that assessed and approved the ethical design of the study. The study is registered on Clinical Trials Registry - India (CTRI/2021/09/036581). ResApp has engaged Triomics, a clinical trial company based in India, to complete the study.

The study will collect cough sounds, symptoms, medical history and a COVID-19 polymerase chain reaction (PCR) test result from each participant. The multi-site study will recruit a total of 220 participants across two study arms: 120 individuals who present for outpatient COVID-19 PCR testing and 100 individuals who are COVID-19 positive and are inpatients at a study site. Inpatients will provide cough sound samples at multiple times during their hospital stay. Study recruitment is expected to be complete by the end of October.

ResApp is using data collected in this clinical study, as well as its two US studies, to develop and train machine learning algorithms to identify COVID-19 from cough sounds recorded on a smartphone.

CEO and Managing Director, Dr Tony Keating commented: 'We are excited to have recruited our first patients in our Indian COVID-19 study. We are confident that with this study, our two COVID-Cough studies in the United States, and our existing pre-COVID respiratory disease cough datasets, we are in a unique position to develop smartphone-based tools to instantly screen for COVID-19 as well as build tools to assist healthcare providers effectively manage COVID-19 positive patients, whether in the home or in healthcare facilities.'


About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.


ResApp Health Limited published this content on 20 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 September 2021 22:41:05 UTC.

© Publicnow 2021
10/10RESAPP HEALTH : ReAapp Health Seeks US FDA Nod for Apnea Assessment Mobile App
10/10RESAPP HEALTH : announces FDA 510(k) submission for SleepCheckRx
10/10Resapp Announces FDA 510(K) Submission for Sleepcheckrx
09/19RESAPP HEALTH : Recruits First Patients in India in COVID-19-Related Cough Sounds Study
09/19RESAPP HEALTH : First patients recruited in COVID-19 clinical study in India
09/19Resapp Health Limited Announces First Patients Recruited in Covid-19 Clinical Study in ..
09/14RESAPP HEALTH : Gets Regulatory Nod for R&D Rebate; Shares Fall 6%
09/13RESAPP HEALTH : receives Advanced and Overseas R&D finding
09/13ResApp Health Limited Receives Advanced and Overseas R&D Finding
09/01RESAPP HEALTH : Secures Indonesian Regulatory Approval for Diagnostic App
More news
Sales 2021 0,07  0,05  0,05 
Net income 2021 -6,77 M -5,05 M -5,05 M
Net cash 2021 6,40 M 4,77 M 4,77 M
P/E ratio 2021 -4,71x
Yield 2021 -
Capitalization 55,8 M 41,8 M 41,7 M
EV / Sales 2020 -
EV / Sales 2021 413 455 192x
Nbr of Employees 500
Free-Float 80,9%
Duration : Period :
ResApp Health Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESAPP HEALTH LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Managers and Directors
Tony Keating Chief Executive Officer, Executive Director & MD
Al Rey Lunar Vice President-Finance
Roger Aston Non-Executive Chairman
Christopher Ntoumenopoulos Non-Executive Director
Brian Leedman Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SNAP INC.50.01%119 488
ANGI INC.-4.66%6 343
GRUBHUB INC.-19.36%5 591
PERFECT WORLD CO., LTD.-48.51%4 757
KAKAO GAMES CORP.57.39%4 585